Navigation Links
Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
Date:1/8/2008

cancer and study participants will be randomized in one of two arms of the trial (1:1), to receive either NKTR-102 and cetuximab or standard irinotecan and cetuximab. The Phase 2b stage is expected to begin in mid-year 2008 and will be conducted in over 40 centers worldwide. The primary endpoint of the Phase 2b trial is progression-free survival. Secondary endpoints include response rate, response duration, overall survival, standard pharmacokinetics, and incidence of toxicities, including diarrhea and neutropenia.

Prior Data Presentations for NKTR-102

Peer-reviewed presentations of preclinical study results for NKTR-102 were presented at ECCO 14 and the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in the fall of 2007. These presentations can be found at: http://www.nektar.com/wt/page/nktr102media

About NKTR-102

Nektar is developing NKTR-102, a PEGylated form of irinotecan, which was invented by Nektar using its world-leading small molecule PEGylation technology platform. The product is currently in Phase 2 clinical development. Irinotecan, also known as Camptosar, is an important chemotherapeutic agent used for the treatment of solid tumors, including colorectal and lung cancers. By applying Nektar's small molecule PEGylation technology to irinotecan, NKTR-102 may prove to be a more powerful and tolerable anti-tumor agent.

Preclinical studies show that treatment with NKTR-102 results in significant suppression of tumor growth in an irinotecan-resistant mouse colorectal tumor model. Administration of NKTR-102 in an animal model results in a significantly improved time-concentration profile for the active metabolite of irinotecan as compared to treatment with standard irinotecan.

About Nektar

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its indu
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
2. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
3. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
4. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
5. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
6. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
7. Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... in two healthcare conferences during the third quarter, the ... Stanley Global Healthcare 2014 Conference.  Alexza,s corporate presentation will ... details on each event are below: , ... 2014 in Boston , MA.  The ...
(Date:7/29/2014)... N.J., July 29, 2014  Covance Inc. (NYSE: ... quarter ended June 30, 2014.  Net revenue was $639 ... 2013.  On a GAAP basis, the company reported earnings ... The company reported pro forma earnings per diluted share ... 2013. Pro forma results exclude asset impairment charges totaling ...
(Date:7/29/2014)... , July 29, 2014 New technology ... which could allow physicians to see and assess brain ... promise, according to study authors who released their findings ... th Annual Meeting in Colorado Springs, ... advance the field of neurointervention, a specialty that facilitates ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3
... Fla., May 08, 2007 /PRNewswire-FirstCall/ --,Viragen, Inc. ... a sponsored in vitro study conducted at ... (multi-,subtype, human alpha interferon) suppressed development of,resistant ... degree than,recombinant alpha interferon. The study has ...
... New Economic Analyses of School and Daycare ... Cost Savings for,Community at Large, TORONTO, May ... research results showing that use of FluMist(R),(Influenza ... school,settings may help reduce the burden of ...
Cached Medicine Technology:Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 2Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 3Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published 4Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 2Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 3Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 4Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 5Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 6Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 7Data Show FluMist May Reduce Seasonal Influenza Burden Among,Children in School, Daycare Settings 8
(Date:7/29/2014)... a well-known online supplier, now allows worldwide clients to ... by providing graceful and sexy lingerie collection for August. ... sexy dresses , designed and developed by top ... price into consideration. Worry no more, because VogueQueen.com launches ... for all clients. , VogueQueen.com’s top designers sincerely ...
(Date:7/29/2014)... Johns Hopkins researchers say they have discovered a chemical ... reactions that, if confirmed in larger studies, could give ... person,s risk of attempting suicide. , The discovery, described ... suggests that changes in a gene involved in the ... a significant role in turning what might otherwise be ...
(Date:7/29/2014)... The One Minute Herpes Cure review indicates that the program ... Alison Freeman wanted to show her patients some alternative ways ... finding out more about this method can easily access it ... currently available in online format. , In the eBook, sufferers ... tips that can help them achieve a cure for herpes. ...
(Date:7/29/2014)... 29, 2014 The Natural Multiple Sclerosis ... inside story to Gary M. Levin’s cure program. ... method for this serious disorder. Levin says that multiple ... that can be found in patients. , Dr. ... For many years, Levin has worked with patients suffering ...
(Date:7/29/2014)... DailyGossip.org reveals in its Stop Sciatica in ... method of naturally overcoming sciatica, in less than 7 ... ensure sufferers that the cure is simple to achieve, ... new method is described as very fast, as it ... 8 minutes per day treatment plan. , Read ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:One Minute to Herpes Cure Review Reveals Simplest Herpes Treatment 2Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2
... Highlights: ... - 100% contract renewal for 11 consecutive annual cycles ... initiative acquisition - Diluted earnings per share of ... Service,Corporation (Nasdaq: PRSC ) today announced financial results for the third,quarter ended ...
... cholesterol-busting drugs could be lifesavers, study suggsts , TUESDAY, ... drugs after coronary artery bypass graft (CABG) surgery reduces ... The study, from the Cleveland Clinic, included more than ... late 2005. The overall incidence of post-operative stroke one ...
... Nationwide,Health Properties, Inc. (NYSE: NHP ) today announced ... investment activity. "The third quarter was a good ... per share up 8%," commented Douglas M. Pasquale, NHP,s,President ... $150,million of accretive investments, bringing our total for 2007 ...
... Nov. 6 The first annual HealthSaver,Caffeinated ... emerging,health care discount service, found that the ... followed by Tampa, Miami, Phoenix and Atlanta. ... The least caffeinated cities are San Francisco/Oakland, ...
... underperformance and ... deterioration of shareholder value., ANAHEIM, Calif., Nov. ... benefit and pension fund trustees and,administrators are in Anaheim, ... conference. The conference is,considered a premier marketing opportunity for ...
... Research has shown convincing evidence that dietary patterns ... decline and dementia risk. An article published in Annals ... on the benefits of diets high in fruit, vegetables, ... reducing dementia risk. , Adults with diabetes are ...
Cached Medicine News:Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 2Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 3Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 4Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 5Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 6Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 7Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 8Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 9Health News:Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 10Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 2Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 3Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 4Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 5Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 6Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 7Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 8Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 9Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 10Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 11Health News:NHP Reports Third Quarter 2007 Revenue and FFO Growth and Enhanced Disclosure Information 12Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 2Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 3Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 4Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 5Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 6Health News:Caffeine Survey Reveals Most, Least Caffeinated Cities 7Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 2Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: